If you've ever watched a glass blower at work, you've seen a material behaving in a very special way. As it cools, the viscosity of molten glass increases steadily but gradually, allowing it to be ...

A few years ago, during a taxi ride, the driver described to me how a pig had transformed his life. A childhood with dogs taught him what to expect from animals, yet he was unprepared for the pig he ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals, Inc. before investing. In this article, we go over a ...

Exclamation marks, ellipses and ‘haha’ can’t fix our growing inability to communicate. By Nitsuh Abebe “How Many Exclamation Points Are Too Many in an Email? A Psychologist Weighs In.” A psychologist!

The percentage of teachers who are using artificial intelligence-driven tools in their classrooms nearly doubled between 2023 and 2025, according to data from the EdWeek Research Center. In 2023, a ...

In the gritty underbelly of crisscrossing highways, Tacoma’s coffee pot-shaped dive bar has lost its color — temporarily — as the owner, just a few years into his stewardship of the century-old icon, ...

Dr. Shech is a professor of philosophy who specializes in the philosophy of science. As popular mistrust of expert opinion grows, we increasingly encounter the following skeptical argument about ...

One year ago, Sam Altman, the C.E.O. of OpenAI, made a bold prediction: “We believe that, in 2025, we may see the first AI agents ‘join the workforce’ and materially change the output of companies.” A ...

Starting a business from home is common, but using a personal address comes with hidden risks. Many founders only realize the impact after facing legal, operational or credibility issues. Many small ...

Nearly six years after the pandemic prompted a new remote work era, return to office battles are back in the news, from Instagram chief Adam Mosseri saying he wants everyone in the office five days a ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

We may receive a commission on purchases made from links. While advancements in chip architecture and battery efficiency have played a major role in the slimming down of computers, we've had to make ...